Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL

To elucidate dynamic changes in native BCR‐ABL and alternatively spliced tyrosine kinase inhibitor (TKI)‐resistant but function‐dead BCR‐ABL(Ins35bp) variant, following commencement or discontinuation of TKI therapy, each transcript was serially quantified in patients with chronic myeloid leukemia (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuda, Junichiro, Odawara, Jun, Minami, Mariko, Muta, Tsuyoshi, Kohno, Kentaro, Tanimoto, Kazuki, Eto, Tetsuya, Shima, Takahiro, Kikushige, Yoshikane, Kato, Koji, Takenaka, Katsuto, Iwasaki, Hiromi, Minami, Yosuke, Ohkawa, Yasuyuki, Akashi, Koichi, Miyamoto, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385367/
https://www.ncbi.nlm.nih.gov/pubmed/32314454
http://dx.doi.org/10.1111/cas.14424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385367/
https://www.ncbi.nlm.nih.gov/pubmed/32314454
http://dx.doi.org/10.1111/cas.14424

Ejemplares similares